Suppr超能文献

miR-424-5p 增强乳腺癌细胞对紫杉醇的化疗敏感性,并调节细胞周期、凋亡和增殖。

MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation.

机构信息

Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Mol Biol Rep. 2021 Feb;48(2):1345-1357. doi: 10.1007/s11033-021-06193-4. Epub 2021 Feb 8.

Abstract

Combination therapy has been considered as a potential method to overcome the BC chemoresistance. MicroRNAs (miRs) have been suggested as a therapeutic factor in the combination therapy of BC. This project aimed at examining the possible activity and molecular function of miR-424-5p and Taxol combination in the human BC cell line. MDA-MB-231 cells were treated with miR-424-5p mimics and Taxol, in a combined manner or separately. We used the MTT test for assessing the cell proliferation. In addition, flow-cytometry was used for evaluating apoptosis and cell-cycle. Expression levels of underlying molecular factors of miR-424-5p were assessed using western-blotting and qRT-PCR. The obtained results demonstrated that miR-424-5p repressed BC cell proliferation and sensitized these cells to Taxol treatment through the induction of apoptosis. Further investigations showed that miR-424-5p might increase BC chemosensitivity through the regulation of apoptosis-related factors including P53, Caspase-3, Bcl-2, and Bax as well as the proliferation-related gene c-Myc. Moreover, miR-424-5p restoration in combination with Taxol treatment decreased the colony formation by regulating Oct-4 and led to G2 arrest via modulating Cdk-2 expression. Western-blotting demonstrated that miR-424-5p may perform its anti-chemoresistance role by regulating the PD-L1 expression and controlling PTEN/PI3K/AKT/mTOR. Overall, the upregulation of miR-424-5p was indicated to upregulate the sensitivity of BC cells to treatment with Taxol. MiR-424-5p might regulate the chemosensitivity of the BC cell line by modulating PD-L1 and controlling the PTEN/mTOR axis. Therefore, the combination of miR-424-5p with Taxol would represent a novel procedure to treat against BC.

摘要

联合治疗被认为是克服乳腺癌化疗耐药性的一种潜在方法。microRNAs(miRs)已被认为是乳腺癌联合治疗的治疗因素。本项目旨在研究 miR-424-5p 和紫杉醇联合治疗人乳腺癌细胞系的可能活性和分子功能。MDA-MB-231 细胞用 miR-424-5p 模拟物和紫杉醇联合或单独处理。我们使用 MTT 试验评估细胞增殖。此外,流式细胞术用于评估细胞凋亡和细胞周期。使用 Western blot 和 qRT-PCR 评估 miR-424-5p 潜在分子因子的表达水平。研究结果表明,miR-424-5p 通过诱导细胞凋亡抑制乳腺癌细胞增殖,并使这些细胞对紫杉醇治疗敏感。进一步的研究表明,miR-424-5p 可能通过调节凋亡相关因子,包括 P53、Caspase-3、Bcl-2 和 Bax 以及增殖相关基因 c-Myc,来增加乳腺癌的化疗敏感性。此外,miR-424-5p 恢复与紫杉醇联合治疗通过调节 Oct-4 减少集落形成,并通过调节 Cdk-2 表达导致 G2 期阻滞。Western blot 表明,miR-424-5p 可能通过调节 PD-L1 的表达和控制 PTEN/PI3K/AKT/mTOR 来发挥其抗化疗耐药作用。总的来说,miR-424-5p 的上调表明可提高乳腺癌细胞对紫杉醇治疗的敏感性。miR-424-5p 可能通过调节 PD-L1 并控制 PTEN/mTOR 轴来调节乳腺癌细胞系的化疗敏感性。因此,miR-424-5p 与紫杉醇的联合治疗可能代表一种治疗乳腺癌的新方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验